Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Qing Fei Pai Du Tang (mQFPD) is a traditional Chinese medicine (TCM) herbal formulation developed by the University of California, San Diego, for the treatment of mild-to-moderate COVID-19 in outpatients. It is a 21-herb formula derived from the classic Qing Fei Pai Du Tang, which itself is a combination of four traditional remedies described in the *Shang Han Lun*: Ma Xing Shi Gan Tang, She Gan Tang, Xiao Chai Hu Tang, and Wu Ling San. The formula is designed to support respiratory function and maintain normal body temperature. It has been evaluated in a Phase 1 randomized, double-blind, placebo-controlled clinical trial to assess its safety and feasibility in self-quarantined patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified Qing Fei Pai Du Tang (University of California, San Diego).